Resuscitation Fluids as Drugs: Targeting the Endothelial Glycocalyx
Fluid resuscitation is a cornerstone of treatment in critically ill patients, with the primary goal of restoring tissue perfusion. However, the choice of resuscitation fluid can have profound effects on the integrity of the endothelial glycocalyx, a critical structure that lines the luminal side of blood vessels. The glycocalyx plays a pivotal role in regulating vascular permeability, microcirculatory perfusion, and leukocyte adhesion. Its degradation, often caused by inflammatory reactions, hypoperfusion, and shock, is associated with poor outcomes in critically ill patients. Therefore, maintaining or restoring glycocalyx integrity has emerged as a high-priority therapeutic strategy. This article explores the effects of various resuscitation fluids on the glycocalyx, highlighting the potential benefits and harms of different fluid types.
Structure and Function of the Endothelial Glycocalyx
The endothelial glycocalyx is a gel-like layer, approximately 0.5 to 5.0 micrometers thick, that lines the luminal side of the endothelium. It is composed of membrane-bound proteoglycans (PGs), glycoproteins, glycosaminoglycans (GAGs), and associated plasma proteins. Proteoglycans, such as syndecans (SDCs), glypican, and perlecan, are connected by GAG side chains, which include heparan sulfate (HS), chondroitin sulfate (CS), hyaluronic acid (HA), dermatan sulfate, and keratin sulfate. The glycocalyx, in combination with plasma proteins like albumin, forms the endothelial glycocalyx layer (EGL), which helps maintain plasma composition and reduces fluid exudation into tissue spaces.
The glycocalyx serves as a barrier against vascular permeability, preventing interstitial edema during intravascular volume expansion. It also plays a crucial role in microcirculatory perfusion by regulating nitric oxide-mediated vasorelaxation, providing anti-adhesive effects to protect endothelial cells from oxidative stress, and exerting anti-coagulant effects to inhibit microvascular thrombosis. However, critical illnesses such as trauma, sepsis, and hemorrhagic shock often lead to glycocalyx degradation, which is associated with increased vascular permeability, thrombosis, inflammation, and organ dysfunction.
Common Biomarkers of Glycocalyx Degradation
The integrity of the glycocalyx can be assessed using direct bedside imaging techniques or by measuring circulating biomarkers. Orthogonal phase spectrometry and sidestream dark-field imaging are commonly used imaging techniques that evaluate sublingual microvascular thickness or perfusion boundary regions. However, their reliability and relevance to glycocalyx integrity remain questionable. Circulating biomarkers, such as SDC-1, HS, CS, and HA, are more commonly used in clinical practice. Among these, SDC-1 is the most abundant proteoglycan and is considered a reliable marker of glycocalyx degradation. Elevated levels of SDC-1 are associated with increased vascular permeability and worse outcomes in trauma patients.
Factors Affecting Glycocalyx Integrity During Fluid Resuscitation
The timing, volume, and rate of fluid administration, as well as the type of resuscitation fluid, can significantly impact glycocalyx integrity. Large fluid volumes during resuscitation have been associated with glycocalyx degradation, potentially due to the release of atrial natriuretic peptide induced by hypervolemia. Oscillatory shear stress caused by rapid intravenous infusion may also contribute to glycocalyx shedding. However, studies comparing faster versus slower infusion rates have shown no significant differences in glycocalyx degradation or clinical outcomes. The timing of fluid resuscitation may also play a role, with early administration potentially being more beneficial than delayed infusion.
Effects of Different Resuscitation Fluids on the Glycocalyx
Normal Saline (NS) and Balanced Crystalloids
Normal saline (NS) is widely used in clinical practice, but it has been associated with glycocalyx degradation in animal studies. In a pig model of hemorrhagic shock, NS led to greater glycocalyx shedding compared to balanced crystalloids like Plasma-Lyte. Similarly, in vitro studies have shown that NS exacerbates glycocalyx degradation in endothelial cells exposed to inflammatory cytokines. Hypernatremia induced by NS may be a contributing factor to this degradation. Despite these findings, clinical studies have not consistently confirmed the harmful effects of NS on the glycocalyx.
Balanced crystalloids, such as lactated Ringer (LR) solution, have been shown to be superior to NS in reducing glycocalyx shedding in animal models. However, the effects of balanced crystalloids on the glycocalyx remain unclear, as most studies did not account for differences in infusion rates or volumes. Some animal studies suggest that balanced crystalloids may also contribute to glycocalyx degradation, highlighting the need for further research.
Synthetic Colloids: Hydroxyethyl Starch (HES), Gelatin, and Dextran
Synthetic colloids, particularly hydroxyethyl starch (HES), have been shown to protect and restore glycocalyx integrity in animal models. In a rat model of acute normovolemic hemodilution, HES preserved the glycocalyx more effectively than balanced crystalloids. Similarly, HES has been shown to downregulate enzymes like heparinase, hyaluronidase, and neuraminidase, which are involved in glycocalyx degradation. However, the use of HES is associated with serious adverse events, including acute kidney injury (AKI) and coagulation dysfunction, limiting its clinical use.
Gelatin and dextran, other synthetic colloids, have been less studied. Gelatin has been shown to exacerbate glycocalyx shedding in animal models, while dextran is rarely used due to its association with coagulation dysfunction and allergic reactions.
Albumin and Balanced Crystalloids
Albumin, a natural colloid, has been extensively studied for its potential to protect and restore the glycocalyx. Animal studies have shown that albumin administration can restore glycocalyx thickness and reduce vascular permeability. In a rat model of hemorrhagic shock, albumin partially restored the glycocalyx and decreased plasma SDC-1 levels. Clinical studies have also suggested that albumin may protect the glycocalyx in patients undergoing surgery. However, some studies have questioned the protective effects of albumin, with one clinical trial showing no reduction in SDC-1 levels after albumin administration.
Balanced crystalloids, while widely used, have unclear effects on the glycocalyx. Some studies suggest they may aggravate glycocalyx degradation, but these findings are often confounded by differences in infusion rates and volumes.
Plasma
Plasma, particularly fresh frozen plasma (FFP), has been shown to restore glycocalyx integrity in animal models. In a rat model of hemorrhagic shock, FFP was more effective than NS, balanced crystalloids, and albumin in restoring the glycocalyx. Plasma administration has also been associated with decreased SDC-1 levels in critically ill patients, suggesting a reduction in glycocalyx shedding. However, the use of plasma is limited by its association with allergic reactions and other adverse events. High-quality clinical studies are needed to confirm the protective effects of plasma on the glycocalyx.
Conclusion
The endothelial glycocalyx is a critical structure that regulates microcirculatory perfusion and vascular permeability. Its degradation, often caused by inflammatory reactions, hypoperfusion, and shock, is associated with poor outcomes in critically ill patients. Fluid resuscitation, while essential for restoring tissue perfusion, can have significant effects on glycocalyx integrity. Normal saline has been associated with glycocalyx degradation in animal studies, but clinical evidence is lacking. Hydroxyethyl starch (HES) has shown promise in protecting and restoring the glycocalyx, but its use is limited by serious adverse events. Albumin has been shown to restore glycocalyx integrity in some studies, but its effects remain controversial. Plasma, particularly fresh frozen plasma (FFP), has demonstrated protective effects on the glycocalyx in animal models, but high-quality clinical studies are needed to confirm these findings.
As our understanding of the glycocalyx deepens, it is likely to become a new therapeutic target in fluid resuscitation strategies. Future research should focus on elucidating the precise mechanisms by which different resuscitation fluids affect the glycocalyx and on developing strategies to minimize glycocalyx degradation during fluid therapy.
doi.org/10.1097/CM9.0000000000001869
Was this helpful?
0 / 0